Cancer Research Institute (CRI) Initial Protocol Concept
Research Admin Offices:
The program will provide up to USD $1 million for novel immunotherapy clinical trials.
- Health Sciences
Internal Deadline:April 17, 2023
Sponsor Deadline:May 1, 2023
- Internal Initial Protocol Deadline - November 17, 2022
- Sponsor Initial Protocol Deadline - December 1, 2022
- Internal Full Application Deadline *by invitation only - April 17, 2023
- Sponsor Full Application Deadline *by invitation only - May 1, 2023
The Cancer Research Institute (CRI) is launching a clinical trials program to support innovative clinical studies from clinicians and academic researchers with the goal of advancing immunotherapies that will provide the greatest impact on patient outcomes. CRI will prioritize selection of trials that address areas of high unmet need in cancer and seek mechanistic insights using deep correlative studies. To maximize the impact of each clinical trial, CRI will advise on selected studies to coordinate and optimize clinical trial design and translational studies.
- Candidates for a clinical trial grant must be the Principal Investigator (PI) of the proposed study.
- CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools or research centers in the United States or abroad.
- Please note that CRI does not support research at for-profit institutions.
The Initial Protocol Concept must be submitted electronically using the CRI online submission portal.
If this is the first time you are submitting a grant application to CRI you will be asked to create a new user account to catalogue all applications submitted to CRI.
If applying from the Faculty of Health Sciences, unless otherwise indicated, you no longer need to send documents to HRS Intake. Your first point of contact is your assigned Senior Grants Advisor.